Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/07/05 12:05:12」(JST)

wiki en

Phenprocoumon (marketed under the brand names Marcoumar, Marcumar and Falithrom) is a long-acting oral anticoagulant drug, a derivative of coumarin. It is a vitamin K antagonist that inhibits coagulation by blocking synthesis of coagulation factors II, VII, IX and X. It is used for the prophylaxis and treatment of thromboembolic disorders (thrombosis/pulmonary embolism). It is the standard coumarin used in Germany.

Phenprocoumon is a 4-hydroxycoumarin and inhibits vitamin K epoxide reductase.^[1]

References

^ Phenprocoumon at PharmGKB

External links

DDB 29943

This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. ワルファリンおよびその他のビタミンK拮抗剤の治療使用 therapeutic use of warfarin and other vitamin k antagonists
2. ワルファリン関連出血または高用量INRのマネージメント management of warfarin associated bleeding or supratherapeutic inr
3. INRコントロールに対するワルファリンとモジュレーターの生物学 biology of warfarin and modulators of inr control
4. ビタミンＫとγカルボキシグルタミン酸の合成および機能 vitamin k and the synthesis and function of gamma carboxyglutamic acid
5. 人工心臓弁のある妊婦のマネージメント management of pregnant women with prosthetic heart valves

English Journal

Half-dose enoxaparin vs. full-dose enoxaparin for postoperative bridging therapy in patients after cardiac surgery: Which dose regimen should be preferred?

Weiss A, Brose S, Ploetze K, Matschke K.SourceDepartment of Cardiac Surgery, University of Technology Dresden, Dresden, Germany.
Clinical hemorheology and microcirculation.Clin Hemorheol Microcirc.2013 May 6. [Epub ahead of print]
BACKGROUND: Patients who require oral anticoagulation (OAC) after cardiac surgery due to an increased risk for thromboembolic events should receive bridging therapy with heparin until the INR is in a therapeutic range. For this purpose, unfractionated heparin (UFH) or low molecular weight heparin (L
PMID 23648452

Meta-Analysis of Rivaroxaban and Bleeding Risk.

Wasserlauf G, Grandi SM, Filion KB, Eisenberg MJ.SourceDivision of Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital/McGill University, Montreal, Quebec, Canada; Faculty of Medicine, McGill University, Montreal, Quebec, Canada.
The American journal of cardiology.Am J Cardiol.2013 May 1. pii: S0002-9149(13)00915-6. doi: 10.1016/j.amjcard.2013.03.054. [Epub ahead of print]
Rivaroxaban, a factor Xa inhibitor, is a new oral anticoagulant that has been developed as an alternative to vitamin K antagonists. However, its safety remains unclear. Reported randomized controlled trials comparing the safety of rivaroxaban with that of vitamin K antagonists (warfarin, acenocoumar
PMID 23642380

Quantifying the effect of covariates on concentrations and effects of steady-state phenprocoumon using a population pharmacokinetic/pharmacodynamic model.

Abduljalil K, Lazar S, Natanzon M, Wu W, Zadoyan G, Steffens B, Kohl V, Mörike K, Tomalik-Scharte D, Stingl J, Schwab M, Harenberg J, Gleiter C, Fuhr U.SourceDepartment of Pharmacology, Clinical Pharmacology Unit, University Hospital, University of Cologne, Gleueler Straße 24, 50931, Cologne, Germany.
Clinical pharmacokinetics.Clin Pharmacokinet.2013 May;52(5):359-71. doi: 10.1007/s40262-013-0043-z.
BACKGROUND AND OBJECTIVES: The oral anticoagulant phenprocoumon, similar to other vitamin K antagonists, is characterized by pronounced interindividual variability in the doses needed to achieve the desired therapeutic effect. Previous studies assessed the effect of genetic and demographic covariate
PMID 23519598

Japanese Journal

Fatal intoxications by acenocoumarol, phenprocoumon and warfarin : Method validation in blood using the total error approach

DENOOZ Raphael,DOUAMBA Zoenabo,CHARLIER Corinne
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 877(23), 2344-2348, 2009-08-01
NAID 10028021440

Phenprocoumon poisonings

RIESSELMANN Benno,HOLLMANN Tanja,TSOKOS Michael
Legal medicine 11, S503-S505, 2009-04-01
NAID 10027263688

A rapid method for the quantification of the enantiomers of Warfarin, Phenprocoumon and Acenocoumarol by two-dimensional-enantioselective liquid chromatography/electrospray tandem mass spectrometry

VECCHIONE Gennaro,CASETTA Bruno,TOMAIUOLO Michela,GRANDONE Elvira,MARGAGLIONE Maurizio
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 850(1), 507-514, 2007-05-01
NAID 10025798809

Related Pictures

★リンクテーブル★

リンク元	「フェンプロクーモン」「フェンプロクモン」

「フェンプロクーモン」

Phenprocoumon
Systematic (IUPAC) name
	(RS)-4-hydroxy-3-(1-phenylpropyl)-2H-chromen-2-one
Clinical data
Trade names	Marcoumar, Marcumar, Falithrom
AHFS/Drugs.com	International Drug Names
MedlinePlus	a699003
Legal status
Legal status	℞ (Prescription only);
Pharmacokinetic data
Protein binding	99%
Metabolism	hepatic to inactive metabolites
Biological half-life	5 to 6 days
Identifiers
CAS Number	435-97-2
ATC code	B01AA04 (WHO)
PubChem	CID 9908
IUPHAR/BPS	6839
DrugBank	DB00946
ChemSpider	10441592
UNII	Q08SIO485D
KEGG	D05457
ChEBI	CHEBI:50438
ChEMBL	CHEMBL1465
Chemical data
Formula	C18H16O3
Molar mass	280.318 g/mol
	SMILES OC=1c3ccccc3OC(=O)C=1C(CC)c2ccccc2 ;
	InChI InChI=1S/C18H16O3/c1-2-13(12-8-4-3-5-9-12)16-17(19)14-10-6-7-11-15(14)21-18(16)20/h3-11,13,19H,2H2,1H3 ; Key:DQDAYGNAKTZFIW-UHFFFAOYSA-N ;
(verify)